We updated the design of this site on September 25th. Learn more.

Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease

This study has suspended participant recruitment.

(Adequate no. of patients could not be recruited in the set time frame.)

Sponsor:

ClinicalTrials.gov Identifier:

NCT00976430

First Posted: September 14, 2009

Last Update Posted: March 9, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Dr Paresh Doshi, Jaslok Hospital and Research Centre

Purpose

This study is intended to look at the safety and efficacy of the use of autologous bone marrow derived stem cell transplant in patients with advanced Parkinson's disease.

Condition	Intervention
Parkinson's Disease	Procedure: Autologous Bone marrow derived stem cells transplant


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	To Study the Safety and Efficacy of Bone Marrow Derived Mesenchymal Stem Cells Transplant in Parkinson's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Parkinson disease

MedlinePlus related topics: Parkinson's Disease

U.S. FDA Resources

Further study details as provided by Dr Paresh Doshi, Jaslok Hospital and Research Centre:

Primary Outcome Measures:

Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests. [ Time Frame: Up to 18 months from the day of stem cell transplant. ]


Estimated Enrollment:	5
Study Start Date:	July 2009
Primary Completion Date:	November 30, 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Therapy for Parkinson's disease Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.	Procedure: Autologous Bone marrow derived stem cells transplant Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum. Other Names: stem cells cell therapy for Parkinson's disease

Detailed Description:

Parkinson's disease, a neurodegenerative disorder, still at its best can only be controlled by medical or surgical treatment. For more than two decades various groups have tried using modified cell transplants for curing this disease. Earlier results with use of fetal mesencephalic cell transplant were encouraging, but this had to be discontinued due to severe side effects.

Current interest, in the use of Mesenchymal stem cells as a pluripotent cell for developing neural cells has been the background for this study. Reliance Life sciences had found encouraging results with the use of human MSCs in Rat model of PD. Based on this and other data, Jaslok Hospital and Research Centre has initiated a pilot study to investigate the efficacy of Autologous MSCs in treating advanced PD. This cells will be harvested from bone marrow, processed at RLS laboratory and transplanted by stereotactic techniques into the striatum of the patient.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	35 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Male or female between 35-70 years of age.
Patient with current diagnosis of PD with motor complications (as confirmed by neurologist) as per the standard criteria and guidelines.
Patients with at least 5 years since the disease.
Responsiveness to Levodopa or dopa agonist. This is defined as improvement between Off and On UPDRS by at least 33% of the Motor UPDRS.
PD of Stage 2.5, 3 & 4 of HOEHN & YAHR staging.
Stable Parkinsonian medications for the 60 days prior to the surgical therapy.
MRI not showing gross atrophy or any other pathology of brain.
Patients with score less than 19 for the Montgomery-Asberg Rating Scale (MADRS) for Depression.
NO Significant cognitive impairment.MMSE > 24.
The participant is able to comply with and understand the required visit schedule and all required tests and procedures.
The participant (and/or LAR) must sign an informed consent.

Exclusion Criteria:

History of intracranial surgeries or implantation of a device for Parkinson's disease two years prior to treatment.
History of psychiatric disorders like schizophrenia or psychotic disorders.
History of other malignancy, with the exception of treated cutaneous squamous cell or basal cell carcinoma, within 5 years.
Contraindication for MRI
General medical contraindications for surgery like coagulopathy
Subjects with abnormal hematology and chemistry values, unless the out of range values are clinically significant with respect to general surgery.
Severe skin infection or osteomyelitis at the site of bone marrow aspiration potentially limiting the procedure.
Positive test results for HIV.
History of drug or alcohol abuse
Pregnant or nursing women

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00976430

Locations


India
Jaslok Hospital And Research Centre
Mumbai, Maharashtra, India, 400026

Sponsors and Collaborators

Jaslok Hospital and Research Centre

Investigators


Principal Investigator:	Paresh k Doshi, MCh	Incharge Stereotactic and functional Neurosurgery,Jaslok Hospital and Research Centre.

More Information

Publications:

Arias-Carrión O, Yuan TF. Autologous neural stem cell transplantation: a new treatment option for Parkinson's disease? Med Hypotheses. 2009 Nov;73(5):757-9. doi: 10.1016/j.mehy.2009.04.029. Epub 2009 May 24.


Responsible Party:	Dr Paresh Doshi, In-charge Stereotactic and Functional neurosurgery, Jaslok Hospital and Research Centre
ClinicalTrials.gov Identifier:	NCT00976430 History of Changes
Other Study ID Numbers:	JHC525
First Submitted:	September 11, 2009
First Posted:	September 14, 2009
Last Update Posted:	March 9, 2017
Last Verified:	March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Keywords provided by Dr Paresh Doshi, Jaslok Hospital and Research Centre:


Autologous Stem Cells.

Additional relevant MeSH terms:


Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases	Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases

To Top